IP Library › Granted Patent US 12,435,342
Granted Patent B2
US 12,435,342 · App. 18/059,269 · Granted Oct 7, 2025

Methods of packaging multiple adeno-associated virus vectors

Inventors: Barry John Byrne (Gainesville, FL); Phillip A. Doerfler (Gainesville, FL); Nathalie Clement (Gainesville, FL)
Assignee: University of Florida Research Foundation, Incorporated
C12N15/86C12N7/00C12Q1/701C12N2750/14143C12N2750/14152C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,435,342
App. No.
18/059,269
Granted
Oct 7, 2025
Kind
B2
Abstract

Provided herein are methods related to co-packaging of multiple rAAV particles. e.g., by introducing multiple nucleic acid vectors encoding proteins or polypeptides or RNAs of interest into a single cell preparation.

Claims (38)

1. A producer cell preparation for producing one or more recombinant adeno-associated virus particles, the producer cell preparation comprising:

a first nucleic acid vector containing a first construct, the first construct comprising a heterologous nucleic acid region encoding a first protein or polypeptide, and

a second nucleic acid vector containing a second construct, the second construct comprising a heterologous nucleic acid region encoding a second protein or polypeptide, wherein the first nucleic acid vector and the second nucleic acid vector are present at an initial ratio,

wherein the producer cell preparation is configured to produce a particle preparation comprising:

a first rAAV particle comprising the first construct, and

a second rAAV particle comprising the second construct, wherein the particle preparation comprises a target ratio of the first rAAV particle to the second rAAV particle within 15% of the initial ratio of the first nucleic acid vector to the second nucleic acid vector.

2. The producer cell preparation of claim 1 , wherein the first and the second nucleic acid vectors each comprise nucleic acid regions comprising an inverted terminal repeat (ITR) flanking each side of the respective heterologous nucleic acid region.

3. The producer cell preparation of claim 1 , wherein the particle preparation comprises a target ratio of the first rAAV particle to the second rAAV particle within 10% of the initial ratio of the first nucleic acid vector to the second nucleic acid vector.

4. The producer cell preparation of claim 1 , wherein the first rAAV particle and the second rAAV particle are each rAAV9 particles.

5. The producer cell preparation of claim 1 , further comprising one or more helper plasmids.

6. The producer cell preparation of claim 1 , further comprising a first helper plasmid comprising a rep gene and a cap gene and a second helper plasmid comprising an E1a gene, an E1b gene, an E4 gene, an E2a gene, and a VA gene.

7. The producer cell preparation of claim 1 , wherein the initial ratio is 1:1, 1:9, or 9:1 of the first nucleic acid vector to the second nucleic acid vector.

8. The producer cell preparation of claim 1 , wherein the first nucleic acid vector and/or the second nucleic acid vector are a first plasmid and/or a second plasmid.

9. The producer cell preparation of claim 1 , wherein the first nucleic acid vector and the second nucleic acid vector are DNA vectors.

10. A cellular composition, the cellular composition comprising:

a producer cell preparation,

a first nucleic acid vector containing a first construct comprising a heterologous nucleic acid region encoding a first protein or polypeptide and nucleic acid regions comprising an inverted terminal repeat (ITR) flanking each side of the heterologous nucleic acid region;

a second nucleic acid vector containing a second construct comprising a heterologous nucleic acid region encoding a second protein or polypeptide and nucleic acid regions comprising an inverted terminal repeat (ITR) flanking each side of the heterologous nucleic acid region; and one or more helper nucleic acids, wherein

the first nucleic acid vector and the second nucleic acid vector are present at a initial ratio,

a first rAAV particle comprising the first construct, and

a second rAAV particle comprising the second construct, wherein

a ratio of the first rAAV particle to the second rAAV particle is within 15% of the initial ratio of the first nucleic acid vector to the second nucleic acid vector.

11. The cellular composition of claim 10 , wherein the first and the second nucleic acid vectors each comprise nucleic acid regions comprising an inverted terminal repeat (ITR) flanking each side of the respective heterologous nucleic acid region.

12. The cellular composition of claim 10 , wherein the ratio of the first rAAV particle to the second rAAV particle is within 10% of the initial ratio of the first nucleic acid vector to the second nucleic acid vector.

13. The cellular composition of claim 10 , wherein the first rAAV particle and the second rAAV particle are each rAAV9 particles.

14. The cellular composition of claim 10 , further comprising one or more helper plasmids.

15. The cellular composition of claim 10 , further comprising a first helper plasmid comprising a rep gene and a cap gene and a second helper plasmid comprising an E1a gene, an E1b gene, an E4 gene, an E2a gene, and a VA gene.

16. The cellular composition of claim 10 , wherein the initial ratio is 1:1, 1:9, or 9:1 of the first nucleic acid vector to the second nucleic acid vector.

17. The cellular composition of claim 10 , wherein the first nucleic acid vector and/or the second nucleic acid vector are a first plasmid and/or a second plasmid.

18. The cellular composition of claim 10 , wherein the first nucleic acid vector and the second nucleic acid vector are DNA vectors.

19. A composition, the composition comprising:

(a) the supernatant or lysate of a producer cell preparation comprising

(i) a first nucleic acid vector containing a first construct comprising a heterologous nucleic acid region encoding a first protein or polypeptide and nucleic acid regions comprising an inverted terminal repeat (ITR) flanking each side of the heterologous nucleic acid region;

(ii) a second nucleic acid vector containing a second construct comprising a heterologous nucleic acid region encoding a second protein or polypeptide and nucleic acid regions comprising an inverted terminal repeat (ITR) flanking each side of the heterologous nucleic acid region; and

one or more helper nucleic acids,

(b) a first rAAV particle comprising the first construct, and

(c) a second rAAV particle comprising the second construct, wherein

a ratio of the first rAAV particle to the second rAAV particle within 15% of the initial ratio of the first nucleic acid vector to the second nucleic acid vector.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2023
From: BYRNE, BARRY JOHN; DOERFLER, PHILLIP A.; CLEMENT, NATHALIE
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 062900/0613 →
Continuity (4)
Continuation 16989857 · Aug 10, 2020
Continuation 15320707
Provisional Application 62015031 · Jun 20, 2014
Related Publication 20230313230A1 · Oct 5, 2023
References Cited (13)
US 10781459B2 · Byrne et al. · 2020 [cited by applicant]
US 11535867B2 · Byrne et al. · 2022 [cited by applicant]
US 20040121444A1 · Zolotukhin et al. · 2004 [cited by applicant]
US 20040209245A1 · Snyder et al. · 2004 [cited by applicant]
US 20140087444A1 · Bennett et al. · 2014 [cited by applicant]
US 20140336245A1 · Mingozzi et al. · 2014 [cited by applicant]
US 20170218395A1 · Byrne et al. · 2017 [cited by applicant]
International Search Report and Written Opinion mailed Sep. 30, 2015 for Application No. PCT/US2015/036841. [cited by applicant]
International Preliminary Report on Patentability mailed Dec. 29, 2016 for Application No. PCT/US2015/036841. [cited by applicant]
Clement et al., Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum Gene Ther. Aug. 2009;20(8):796-806. doi: 10.1089/hum.2009.094. [cited by applicant]
Sharma et al., Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts. Brain Res Bull. Feb. 15, 2010;81(2-3):273-8. doi: 10.1016/j.brainresbull.2009.07.005. Epub Jul. 1… [cited by applicant]
Shin et al., Recombinant adeno-associated viral vector production and purification. Methods Mol Biol. 2012;798:267-84. doi: 10.1007/978-1-61779-343-1_15. [cited by applicant]
Zeltner et al., Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther. Jul. 2010;17(7):872-9. doi: 10.1038/gt.2010.27. Epub Mar. 25, 2010. [cited by applicant]